ChromaDex Corp. (CDXC)

[someconcerns]

Thank you for refreshing my aging memory.

[someconcerns]

As summarized by MT newswire:

ChromaDex Shares Rally After COVID-19 Patients on Nutrient Recover Faster in Study
BY MT Newswires
— 3:12 PM ET 02/25/2021

03:12 PM EST, 02/25/2021 (MT Newswires) -- ChromaDex ( CDXC ) shares jumped more than 120% Thursday after a late-stage study showed that the addition of a nutritional protocol including nicotinamide riboside helped speed up the recovery of mild-to-moderate COVID-19 patients.

The nutritional addition reduced recovery time and improved liver health while lowering inflammation, according to the trial results published on medRxiv. ChromaDex ( CDXC
Loading... Loading...
) markets Tru Niagen, a cellular nutrient used to raise nicotinamide levels.

Separately, the company said it has raised $25 million after selling some 3.85 million shares to institutional investors at $6.50 each. It plans to use the proceeds to grow the Tru Niagen brand and for general corporate purposes.

Price: 22.55, Change: +12.81, Percent Change: +131.52

[Skidoonut]

Notice the 8-k issued today? Give it a read and then decide what that means!

[Wildbilly]

Yes he does going back to the old Safe Stitch days.

[someconcerns]

Whichever cause, my account balances are loving this.

[2020trader]

VERY INTERESTING FOR SURE

[INFINITI]

Blast off

[tredenwater2]

This looks like a takeover attempt. The entire float has traded out of nowhere plus some.

[INFINITI]

For now let’s see

[someconcerns]

Good luck, Infinity. I'm a L-T holder. Cost basis 2-3.40 depending on the account. As you can tell, patience is my long suit; not trading. I assume you are attracted to the action.

[INFINITI]

Looks good got in

[someconcerns]

Thanks. We shall see at some point. SP increase could also be a buy out.

[tredenwater2]

Earnings must be really, really good and someone was waiting for the ph 3 covid trial as cover to “enter”!

[someconcerns]

Even more insane SP. Up 51 percent, with volume 30+X daily average.

[someconcerns]

Don't hold me to spelling, but Patrick Soong Shin?

Clearly, with the surge in SP and the volume after 1.5 hours of 10X the daily average over the last 90 days, someone thinks they know something. I believe Dr. Frost still owns a major number of shares.

[tredenwater2]

Could be stellar earnings about to be reported. New international investor, this stock has been a sleeper with big fish like Zuckerberg (billionaire) Frost (billionaire), the other ((billionaire) Hong Kong investor( for get his name) soaking up the float ahead of earnings yet crickets.

Their science says it works and nobody cares.

[someconcerns]

Why the gap up today (Feb 25, 2021)?

[swampboots]

RE: higher NAD+, this was just reported:
https://medicalxpress.com/news/2020-11-chronic-inflammation-reduction-nad.html

[RulerofNations]

Higher NAD+ May Boost Immunity to Coronaviruses
From the Journal of Biological Chemistry:
"These data suggest that the antiviral activities of noncanonical PARP isozyme activities are limited by the availability of NAD, and that nutritional and pharmacological interventions to enhance NAD levels may boost innate immunity to coronaviruses."

Source: insert-text-here

[tredenwater2]

Thanks I googled the same after posting.

[tredenwater2]

Thanks I googled the same after posting.

[bryanb40]

https://www.investopedia.com/terms/c/confidential-treatment-order.asp

[tredenwater2]

Anybody know what a confidential treatment order is and why this company is using one? Long haul for shareholders and all they can produce is a CTO?

[whytestocks]

JUST IN: $CDXC ChromaDex Announces Study Results Showing Nutritional Protocol Including Nicotinamide Riboside Plus Standard of Care Reduces Recovery Time in COVID-19 Patients by Nearly 30%

Phase 2 study finds addition of nutritional protocol to standard of care reduces recovery time to 6.6 days from 9.3 in mild-to-moderate COVID-19 patients ChromaDex Corp. (NASDAQ:CDXC) today announced that results from the study “Combined metabolic cofactor supplementa...

In case you are interested CDXC - ChromaDex Announces Study Results Showing Nutritional Protocol Including Nicotinamide Riboside Plus Standard of Care Reduces Recovery Time in COVID-19 Patients by Nearly 30%

[weasel4339]

Wakey wakey

[tredenwater2]

Absolutely amazing this message board has dried up as soon as the lawsuit is over. Price has also stabilized....hmmmm!

Oan my wife said she just saw a true niagen commercial on a network tv channel. Just a matter of time until this company gets bought out. Will Dr Frost and Nane Hasaio let this happen or will OPKO “absorb” Chromadex?

Tred

[Monroe1]

thanks for sharing. Good info good research.

[Milarepa]

Oral Argument Before CAFC on Elysium's Claim:
This morning Elysium got to argue its case on Claim 2 of the '086 Patent before the Court of Appeals for Federal Circuit. It didn't go great for Elysium.
https://www.right-of-assembly.org/post/oral-argument-before-the-cafc

[Southern Gal]

First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension

Study expands on recently published preclinical data that showed improvements in aerobic performance following supplementation with ChromaDex’s novel form of vitamin B3

LOS ANGELES, Jan. 06, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (CDXC), the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced today the initiation of a first-of-its-kind Phase 1 clinical study sponsored by the University of Florida, in collaboration with the National Institute on Aging. This trial will assess the potential of NIAGEN® (NR) to enhance the effects of exercise therapy in older adults with hypertension. ChromaDex’s patent-protected NR is a unique form of vitamin B3 that is proven to safely increase NAD+ levels in the body. NAD+ declines as we age and is a critical coenzyme for cellular energy production and mitochondrial function, both important components of healthy human aging.

About one third of U.S. adults have hypertension, putting them at greater risk of cardiovascular disease, or even death. The benefits of exercise in helping to manage hypertension and enhance cardiovascular health are well documented. However, as individuals age, continuing a regular exercise routine can become more challenging due to age-associated physiological declines.

“This clinical trial will provide valuable information on the potential of NR supplementation to enhance the benefits of exercise in older populations with hypertension. Published data suggest NR may support cardiovascular health with further study, specifically through improvements in blood pressure (BP) and aortic stiffness. However, older hypertensive adults have yet to be explored in a clinical study,” said primary investigator Robert Mankowski, PhD, Department of Aging and Geriatric Research, the University of Florida.

This new randomized, double-blind study will evaluate the impact of NR supplementation combined with exercise in 74 hypertensive adults as measured by changes in arterial stiffness, blood pressure and walking performance. It was initiated as part of the ChromaDex External Research Program (CERP), where ChromaDex supplies its NR and placebo at no cost to research institutions worldwide.

“Through increases in NAD+, NR has the potential to improve cellular energy production, supplying individuals with the energy necessary to maintain a regular exercise routine,” said ChromaDex Chief Scientific Officer Dr. Matthew Roberts. “We look forward to enhancing our understanding of the use of NR as an adjuvant approach to exercise in promoting improvements in the cardiovascular health of aging adults.”

Niagen is the only commercially available nicotinamide riboside which has twice been successfully reviewed under FDA's new dietary ingredient (NDI) notification program and has also been successfully notified to the FDA as generally recognized as safe (GRAS).

[Wildbilly]

Management back to sales and not letting the legal dominate,

nice month so far. Accum/dist needs to continue heading up.

[ClayTrader]

* * $CDXC Video Chart 12-13-2019 * *

Link to Video - click here to watch the technical chart video

[Milarepa]

Here is ChromaDex's Supplemental Brief, spelling out in detail exactly how Elysium's misdeeds caused damages.

https://www.right-of-assembly.org/post/cdxc-s-supplemental-msj-brief

[Milarepa]

What you missed on Right of Assembly:

1. The identity of Elysium's First Mystery NR Supplier Revealed:
https://www.right-of-assembly.org/post/there-is-a-pattern-here-of-behavior

2. ChromaDex Asks to Restart the Patent Infringement Action in Delaware
https://www.right-of-assembly.org/post/chromadex-lift-the-stay-in-delaware

3. Might Elysium's Counsel Withdraw?
https://www.right-of-assembly.org/post/no-way-out-law-firm-edition

[GAB]

Strange, I ordered from the Wal-Mart app for a 30 day supply to be shipped by Tru-Niagen, but just got an e-mail that the order was cancelled with explanation.

[tat4tat]

Weak PPS response to analysts targets. The other day a target of 8 bucks was given and now a 6 bucks target. Great trading opportunities at between 3.71 and 2.82 recently. Will they miss earnings estimates?

[Milarepa]

Thanks! If people like to read it, then I like to write it. My intuition is that Oppenheimer's initiating coverage with an "outperform" recommendation ought to reassure a lot of investors.

[frrol]

Yet another fantastic blog entry. You really elucidate these arcane legal actions and the bigger picture. Keep it up, I find it fascinating as a non-attorney.

[Milarepa]

Trial Delay in California; should we even care?

https://www.right-of-assembly.org/single-post/2019/10/12/WTH-Just-Happened-INVESTORS-GUIDE-to-the-ChromaDex-Litigation

[jfk]

hope that is correct. based on stock action, seems no harm done. thanks

[Wildbilly]

Fried & Farr putting their own $ in since March

http://www.openinsider.com/search?q=cdxc

[Milarepa]

The consensus on the other board seems to be that this is the formal registration of the shares previously issued, which makes them eligible for sale, but does not necessarily evince an intent to sell (and if Li were bailing out we would indeed be alarmed!!!)

[jfk]

Can someone explain the 'private sale'. Is this an especially negative sale that the biggest holders want to dump their holdings in CDXC?

[Milarepa]

California Trial now October 22
https://www.right-of-assembly.org/single-post/2019/09/12/CA-Trial-Delayed-to-October-22

[Wildbilly]

Good get


AgeX ($AGE) CEO Dr. Michael West giving a basic primer on the science.

https://vimeo.com/357713085?ref=em-share

[Jitz]

future merger potential?

https://finance.yahoo.com/news/industry-leaders-aubrey-grey-frank-120000033.html

[Milarepa]

Will Elysium's Damages Expert Get to Testify?
https://www.right-of-assembly.org/single-post/2019/09/06/Cockburn-Testimony----Opposition-and-Reply-Briefs

[Milarepa]

CDXC Reply Brief: Cooley Picks Off a Runner
https://www.right-of-assembly.org/single-post/2019/09/04/CDXC-Reply-ISO-Motion-for-Summary-Judgment

[Milarepa]

Deposition of Elysium CEO Eric Marcotulli:
https://www.right-of-assembly.org/single-post/2019/09/01/The-Marcotulli-Deposition----Yikes

[Milarepa]

New Facts Emerge: the fullest account yet of the alleged trade secret thefts:
https://www.right-of-assembly.org/single-post/2019/08/31/OMG---ChromaDexs-Opposition-Brief-on-Summary-Judgment

[Milarepa]

CAFC Appeal Update: Boring

The PTAB appeal has turned boring; we’ll probably end up in the same place we are right now, with all of the ‘807 patent valid and Claim 2 of the ‘086 patent valid and that’s that.

https://www.right-of-assembly.org/single-post/2019/08/29/CDXC-Files-CAFC-Opposition-Abandons-Cross-Appeal